William G Wierda

Professor

  • 28189 Citations
  • 88 h-Index
1989 …2020
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where William G Wierda is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 91 Similar Profiles
B-Cell Chronic Lymphocytic Leukemia Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
Acute Myeloid Leukemia Medicine & Life Sciences
Cyclophosphamide Medicine & Life Sciences
Leukemia Medicine & Life Sciences
B-Lymphocytes Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1989 2020

Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know

Shah, M., Rajha, E., DiNardo, C., Muckey, E., Wierda, W. G. & Yeung, S. C. J., Feb 2020, In : Annals of emergency medicine. 75, 2, p. 264-286 23 p.

Research output: Contribution to journalReview article

Hematologic Neoplasms
Emergencies
Physicians
Antigen Receptors
Emergency Medicine
T-Cell Prolymphocytic Leukemia
Pentostatin
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide
1 Citation (Scopus)
B-Cell Chronic Lymphocytic Leukemia
Morbidity
Neoplasms
Comorbidity
Therapeutics
1 Citation (Scopus)
Acute Promyelocytic Leukemia
B-Cell Chronic Lymphocytic Leukemia
Tretinoin
Leukemia
Bone Marrow Examination